Research Article
8-Weeks of β-GPA Treatment Reduces Body Mass While Positively Altering Translation Initiation in Obese Skeletal Muscle
| Joshua C. Drake, Lauryn Benninger and David L. Williamson* | |
| Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, SUNY, Buffalo, NY 14214 | |
| Corresponding Author : | David L. Williamson, PhD Assistant Professor University at Buffalo SUNY School of Public Health and Health Professions Department of Exercise and Nutrition Sciences 214A Kimball Tower (office) / 5 Sherman (lab) Buffalo, NY 14214, USA Tel: (716) 829-6758 Fax: (716) 829-2428 E-mail: davidwil@buffalo.edu |
| Received November 08, 2011; Accepted November 19, 2011; Published November 21, 2011 | |
| Citation: Drake JC, Benninger L, Williamson DL (2011) 8-Weeks of β-GPA Treatment Reduces Body Mass While Positively Altering Translation Initiation in Obese Skeletal Muscle. J Obes Weig los Ther 1:101. doi:10.4172/2165-7904.1000101 | |
| Copyright: © 2011 Drake JC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
The aim of this study was to determine how 3-guanidinopropionic acid (?-GPA) treatment, that reduces body mass, alters obese skeletal muscle mass and regulatory mechanisms controlling muscle mass. Lean (L) and ob/ ob (O) mice were fed either a control (C) or a ?-GPA-containing (F) diet for 8 weeks. Body mass decreased in both ?-GPA treated groups. Despite a lower plantar flexor-complex muscle mass, both ?-GPA treated groups achieved the same muscle mass. Raptor-mammalian Target of Rapamycin protein association was lower in OC muscle (vs. LC) and was not altered with ?-GPA, despite reductions in S6K1 activation (OF only). 4E-BP1 phosphorylation increased in the ?-GPA treated groups, but only the OF mice displayed an increase in eIF4E phosphorylation that corresponded with a trending increase in eIF4G-eIF4E association. Thus, long-term ?-GPA treatment augments obesity-induced dysregulation of mechanisms controlling skeletal muscle mass to that of the lean, while reducing body mass.
